However, with the new economic model, the situation began to reverse. “Today, based on the macroeconomic order, stability, and predictability that the National Government promotes, that has started to change,” he affirmed. In this context, health “is consolidating as one of the most dynamic sectors of the Argentine economy.”
The minister highlighted that when “the State organizes, clarifies, and establishes clear rules, the private sector invests, incorporates technology, expands capacities, and generates value.” Under this logic, measures such as purchasing medications at laboratory exit prices were promoted, aiming to reduce costs and encourage competition.
The results are already visible. Companies like SC Johnson, Pfizer, and Sinergium Biotech itself have announced recent investments in the country. Currently, the Argentine pharmaceutical and biotechnology industry produces more than 8.1 billion dollars annually and exports to over a hundred countries.
Additionally, Lugones highlighted the potential in areas such as clinical research, health infrastructure, and technological development applied to health. The expansion of electronic prescriptions, with over 20 million monthly prescriptions, and advancements in artificial intelligence applied to diagnostics are part of this process.
In parallel, the official emphasized the new global scenario, where regional production of vaccines and medicines takes on strategic relevance. In this sense, collaboration with international organizations like PAHO opens new opportunities to strengthen local capacities and expand exports.
“The challenge now is to deepen that process and turn the sector into one of the major engines of the country's growth,” proposed Lugones, in a bid to position Argentina as a central player in the health economy at the regional and international levels.
